Announcements Trials
Browse Landscape

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Radiation Injuries 1Oropharyngeal Neoplasms 1Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1Cholangiocarcinoma 1Cervical Cancer Susceptible Population Classification 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 24Cisplatin 24durvalumab 13pembrolizumab 9Oxaliplatin 7Capecitabine 7Fluorouracil 6Leucovorin 5Bevacizumab 5lenvatinib 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4Nivolumab 3Liquid Biopsy 3Injections 3Folfox protocol 3Carboplatin 3zanidatamab 2trifluridine tipiracil drug combination 2tremelimumab 2tislelizumab 2ivosidenib 2futibatinib 2apatinib 2Trastuzumab 2Taxes 2Irinotecan 2Immune Checkpoint Inhibitors 2Drug Therapy 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Biliary Tract Neoplasms × Base Sequence × Clear all
NCT06648057 2026-03-18

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

CHA University

Recruiting
100 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡